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ABSTRACT We have previously shown that HIV-1-infected children develop broader
and more potent neutralizing antibody responses than adults. This study aimed to
determine the antibody speciﬁcities in 16 HIV-1 subtype C-infected children who dis-
played exceptional neutralization breadth on a 22-multisubtype virus panel. All chil-
dren were antiretroviral treatment (ART) naive with normal CD4 counts despite be-
ing infected for a median of 10.1 years with high viral loads. The speciﬁcity of
broadly neutralizing antibodies (bNAbs) was determined using epitope-ablating mu-
tants, chimeric constructs, and depletion or inhibition of activity with peptides and
glycoproteins. We found that bNAbs in children largely targeted previously deﬁned
epitopes, including the V2-glycan, V3-glycan, CD4bs, and gp120-gp41 interface. Re-
markably, 63% of children had antibodies targeting 2 or 3 and, in one case, 4 of
these bNAb epitopes. Longitudinal analysis of plasma from a mother-child pair over
9 years showed that while they both had similar neutralization proﬁles, the antibody
speciﬁcities differed. The mother developed antibodies targeting the V2-glycan and
CD4bs, whereas bNAb speciﬁcities in the child could not be mapped until 6 years,
when a minor V2-glycan response appeared. The child also developed high-titer
membrane-proximal external region (MPER) binding antibodies not seen in the
mother, although these were not a major bNAb speciﬁcity. Overall, exceptional neu-
tralization breadth in this group of children may be the result of extended exposure
to high antigenic load in the context of an intact immune system, which allowed for
the activation of multiple B cell lineages and the generation of polyclonal responses
targeting several bNAb epitopes.
IMPORTANCE An HIV vaccine is likely to require bNAbs, which have been shown to
prevent HIV acquisition in nonhuman primates. Recent evidence suggests that HIV-
infected children are inherently better at generating bNAbs than adults. Here, we
show that exceptional neutralization breadth in a group of viremic HIV-1 subtype
C-infected children was due to the presence of polyclonal bNAb responses. These
bNAbs targeted multiple epitopes on the HIV envelope glycoprotein previously de-
ﬁned in adult infection, suggesting that the immature immune system recognizes
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HIV antigens similarly. Since elicitation of a polyclonal bNAb response is the basis of
next-generation HIV envelope vaccines, further studies of how bNAb lineages are
stimulated in children is warranted. Furthermore, our ﬁndings suggest that children
may respond particularly well to vaccines designed to elicit antibodies to multiple
bNAb epitopes.
KEYWORDS epitope mapping, HIV envelope targets, HIV vaccines, HIV-1 subtype C,
mother-child transmission, neutralization breadth, neutralizing antibodies, pediatric
immunology, bNAbs
Fundamental differences exist between adult and pediatric HIV infection as a con-sequence of different transmission routes and immaturity of the pediatric immune
system (1). The most signiﬁcant difference is that HIV disease progression is more rapid
in children and is associated with signiﬁcantly higher levels of viral replication (2).
Pediatric HIV infection is biphasic, with approximately 60% of deaths occurring before
3 years. Those children that survive beyond this usually show slow disease progression
(3). About 10% of these children have normal CD4 counts in the context of high viral
burden, which is only rarely seen in adult viremic nonprogressors (4). It was further
shown that these pediatric nonprogressors (PNPs) had reduced CCR5 expression on
long-lived memory CD4 T cells and low levels of immune activation (4). Protective HLA
alleles play a less important role in nonprogressing HIV-1 infection in children, in
contrast to adults (5). Furthermore, in adults, nonpathogenesis is associated with a high
CD4 count and undetectable viral loads, whereas PNPs typically retain a persistently
high viral burden (1, 4, 6). Previous studies have shown that neutralizing antibody
responses in HIV-infected children arise early in the course of infection and are more
potent and more broadly neutralizing than in adult infection (4, 7). These differences
between adults and children provide a rationale for further characterizing humoral
antibody responses during pediatric HIV-1 infection.
Broadly neutralizing anti-HIV antibodies (bNAbs) are considered an important com-
ponent of an HIV vaccine and may also play a critical future role in treatment and cure
strategies (8). Numerous studies have documented the presence of bNAbs in chroni-
cally infected adults (9–13). This has led to the isolation of a large number of broad and
potent neutralizing monoclonal antibodies (MAbs) that have helped to deﬁne major
sites of vulnerability on the HIV envelope, namely, the V2-glycan, V3-glycan, CD4
binding site (CD4bs), gp120-gp41 interface, and the membrane-proximal external
region (MPER) (14). These targets provide a blueprint for immunogen design, although
to date no envelope vaccines have been able to elicit bNAbs.
A previous longitudinal study of bNAbs in children has suggested that they arise
earlier than in adults, and in some cases, bNAbs could be detected within the ﬁrst year
of life (7). Limited mapping data suggested that breadth was mediated either by
multiple bNAb speciﬁcities that could not be deconvoluted or by bNAbs with novel
speciﬁcities (7). Subsequently, a MAb was isolated and characterized from one infant
(15). This bNAb, BF520.1, was shown to target the V3-glycan epitope on the HIV
envelope and exhibited neutralization breadth of 58%. In addition, BF520.1 was shown
to have low levels of somatic hypermutation compared with adult bNAbs targeting the
same epitope, suggesting that the mechanisms governing development of bNAbs in
children are different from those of adults.
We therefore sought to deﬁne bNAb speciﬁcities in a previously reported cohort of
HIV-1 subtype C-infected children over 5 years of age who had high viral loads but
normal CD4 counts and exceptionally high levels of bNAbs (4). Indeed, 70% (61/87) of
children had plasma antibodies that neutralized 50% of viruses compared with only
19% of adults infected for a similar duration (4). In this study, we performed experi-
mental mapping of bNAb speciﬁcities in 16 of these children. We showed that children
develop bNAbs targeting epitopes similar to those of adults. However, we also dem-
onstrated that the majority of children develop a polyclonal bNAb response targeting
as many as four different epitopes. Lastly, we demonstrated that an infected mother-
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child pair developed equivalently high bNAb responses but that these target distinct
neutralization epitopes, highlighting the role of multiple factors in bNAb development.
RESULTS
Clinical features of HIV-1 subtype C-infected children selected for this study.
We selected 16 HIV-1-infected children from two pediatric cohorts of nonprogressors
and progressors plus one transmitting mother for epitope mapping based on their
neutralization breadth and potency, as described in an earlier study (4). Clinical and
demographic features of selected participants are shown in Table 1. The median age of
the children was 10.1 years (interquartile range, 6.5 to 12.9), and all were antiretroviral
treatment (ART) naive at the time of sample collection. The viral load ranged between
1,500 and 490,000 copies/ml, and the absolute CD4 count ranged between 300 and
2,000 cells/mm3. This unusual phenotype of normal CD4 counts in a context of high
viral burden was previously described for the larger cohort from which these children
were selected (4). Neutralization breadth and potency of all 17 plasma samples were
assessed against a multisubtype panel of 22 heterologous viruses (Fig. 1). Neutralization
breadth ranged between 60 and 100%, and the geometric mean titers (GMT) ranged
between 151 and 1,204 (Table 1). Three children plus the transmitting mother neutral-
ized 100% of the subtype A, B, and C viruses. Although there was a signiﬁcant
correlation between neutralization breadth and viral load in the larger cohort (4),
signiﬁcance between these two variables was not maintained in this smaller selected
group of broad neutralizers.
Differential effect of gp120 adsorption on neutralization capacity of plasma
suggests polyclonal bNAb responses. To assess whether gp120-directed antibodies
mediated neutralization breadth, plasma samples were adsorbed with ConC gp120 and
tested against ConC, CAP45, and Q23.17 in a TZM-bl neutralization assay. Enzyme-
linked immunosorbent assays (ELISAs) conﬁrmed the depletion of ConC gp120-binding
antibodies for all plasma samples (data not shown). Adsorption with ConC gp120
resulted in at least a 50% reduction in neutralization activity for 14/16 plasma samples
when tested against ConC, 8/16 samples for CAP45, and 5/16 samples for Q23.17 (Fig.
2). For one child (PID1_C), adsorption did not result in signiﬁcant depletion of neutral-
ization activity (50%) against any of the 3 viruses, suggesting that neutralization
breadth in this child is mediated by trimer-speciﬁc or gp41-directed antibodies. Inter-
estingly, the effect of adsorption of gp120-speciﬁc antibodies on neutralization varied
per virus for most plasma samples. For example, in PID12, gp120-directed antibodies
neutralized ConC, partially neutralized Q23.17, but failed to neutralize CAP45, whereas
TABLE 1 Demographic and clinical features of 17 HIV-1-infected participants selected for epitope mapping
Participant ID Age (yr) Classiﬁcation Absolute CD4 (/mm3) Viral load (copies/ml) % Neutralization breadtha GMTb
PID1_Mc 35.5 Nonprogressor 509 22,000 100 1,204
PID1_Cc 6.5 Nonprogressor 1,553 13,938 100 1,009
PID2 12.9 Nonprogressor 521 490,000 100 328
PID3 10.2 Nonprogressor 756 110,000 100 325
PID4 11.9 Nonprogressor 635 42,000 91 297
PID5 9.6 Nonprogressor 1,622 10,321 91 188
PID6 10.1 Nonprogressor 1,395 50,000 91 151
PID7 10.0 Progressor 327 22,467 91 386
PID8 11.6 Nonprogressor 1,115 6,430 86 197
PID9 8.6 Nonprogressor 1,120 58,400 86 181
PID10 10.7 Nonprogressor 1,330 11,900 82 194
PID11 10.1 Nonprogressor 717 140,000 82 166
PID12 10.5 Progressor 301 71,000 82 343
PID13 6.7 Progressor 334 387,134 82 268
PID14 9.6 Nonprogressor 1,877 4,574 73 450
PID15 11.1 Nonprogressor 1,310 1,585 73 296
PID16 11.5 Nonprogressor 1,032 99,000 60 196
aNeutralization breadth was measured against a multiclade panel of 22 viruses.
bGMT, geometric mean titer.
cMother-child pair.
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in PID10 virtually all the neutralization activity against ConC, CAP45, and Q23.17 was
gp120 directed (Fig. 2). This variable effect of gp120 adsorption by virus suggested that
in most cases, breadth was mediated by polyclonal responses, some of which were
gp120 speciﬁc.
The majority of children develop antibodies targeting the V2-glycan and
V3-glycan epitopes. Pseudoviruses containing mutations at key residues in the V2-
glycan and V3-glycan epitopes were used to screen for these speciﬁcities in plasma
samples. For V2-glycan antibodies, we used both N160A/K and K169E mutants, as some
V2-directed antibodies, such as the CAP256-VRC26 lineage, exhibit limited glycan
dependence (16, 17). Speciﬁcity was assigned when neutralizing activity for the mutant
virus was3-fold less than that of the wild-type virus in 2 or more backbones. By these
criteria, 9 of the 16 children (56%) developed antibodies directed at the V2-glycan
epitope (Fig. 3), although the effect varied by virus backbone. For example, in PID15,
either a 160A or 169E mutation completely abrogated neutralization in CAP45, sug-
gesting that the V2 speciﬁcity accounts for all activity against this virus. However,
neither BG505 nor CAP256_SU was neutralized by V2-directed antibodies, suggesting
that other speciﬁcities in this child were responsible for neutralizing these viruses.
Similarly, a 10-fold effect was observed for PIDs 2, 5, 13, and 14 in CAP45, but the
effect was less pronounced for other backbones. Several plasma samples were more
affected by the K169E mutation than by the N160A mutation in CAP45, suggesting less
dependence on the glycan moiety in this epitope, similar to CAP256 MAbs (16, 17).
Consistent with published data, neutralization by positive-control MAbs CAP256.08 and
PG9 was reduced/knocked out in V2-glycan mutants (16–18).
To assess V3-glycan antibodies, we deleted the N332 glycan in three backbones,
TRO.11, ConC, and Du156.12. Using the same cutoffs, a V3-glycan speciﬁcity was
assigned to a third (5/16, 31%) of the children, of whom four (PIDs 2, 5, 7, and 13) also
showed evidence of V2-glycan-directed bNAbs (Fig. 3). Consistent with previous data
(19), we observed a knockout in neutralization activity for PGT128 against the N332A
mutant in all viruses tested. Overall, our data suggest that bNAbs directed at the
FIG 2 Differential effect of gp120 adsorption on neutralization suggests polyclonality. Anti-gp120
antibodies were depleted from plasma samples of all 16 children using tosyl-activated beads coated with
ConC gp120 protein. Adsorbed plasma were tested for neutralization activity against ConC and heter-
ologous viruses CAP45 and Q23.17. The percentage of gp120-directed neutralization was calculated as
the reduction in ID50 of plasma incubated with gp120-coated beads relative to that of blank beads
[((blank beads gp120-coated beads)/blank beads) 100]. Plasma samples where50% of neutralizing
activity was depleted by gp120 are colored red, and those with no depletion are colored blue. Those with
some gp120-directed antibodies are colored yellow.
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V2-glycan epitope are the most common in HIV-1 subtype C-infected children with
broad neutralizing responses.
CD4bs-directed plasma antibodies are frequently detected in children.We used
the wild-type RSC3 protein and its RSC3Δ371I/P363N mutant to assess CD4bs binding
and neutralization activity. Binding of six plasma samples (PIDs 4, 5, 6, 8, 10, and 11) to
the RSC3Δ371I/P363N CD4bs mutant was signiﬁcantly lower than that to the wild-type
RSC3 protein, suggesting the presence of CD4bs-directed antibodies in these partici-
pants (Fig. 4). This pattern was comparable to that of the positive-control MAb, VRC01
(Fig. 4), which was isolated using this RSC3 probe. Overall, the binding assays demon-
strated that a third of children (6/16, 38%) had CD4bs-directed activity. Protein com-
petition assays using the RSC3 protein veriﬁed CD4bs-directed neutralization activity in
all six children (Fig. 4B). This was conﬁrmed by at least 30% reduction in neutralization
activity following incubation with RSC3 protein. This effect was, however, only observed
in one virus for 5 of the 6 children (Fig. 4B). Incubation with the RSC3Δ371I/P363N
CD4bs mutant did not impact neutralization activity against any of the 4 viruses tested
(data not shown).
In addition to binding assays, neutralization assays were performed using viruses
with mutations in the CD4bs epitope (N276A, N279A, and R456W). The N276 and N279
residues are important contact sites for HJ16-like CD4bs antibodies, while the R456
residue is critical for epitope recognition for VRC01, 3BNC117, N6, and VRC27 (20). No
reduction in neutralization activity was observed with the N276A and N279A mutants
for any participants (data not shown). However, a 4-fold reduction in neutralization
activity using the R456W mutant was observed in two participants (PID4 and PID10)
(data not shown), verifying the data using the RSC3 proteins. Overall, binding and
neutralization assays suggest that 40% of children develop CD4bs-directed antibody
responses that contribute to broad neutralization activity.
Anti-MPER antibodies rarely confer broad neutralizing activity in children. The
presence of MPER-directed antibodies in plasma samples was measured using the
HIV-2/HIV-1 MPER chimeras as previously described (21). Four of 16 children showed
50% reciprocal plasma dilution (ID50) titers of 750 against either C1 (contains the
subtype B HIV-1 MPER sequence) or C1C (subtype C HIV-1 MPER sequence). Fine
FIG 3 Majority of children develop neutralizing antibodies directed at V2-glycan and V3-glycan epitopes. Plasma samples from 16 children were assessed for
V2-glycan antibodies using N160A/K and K169E mutants and for V3-glycan-directed responses using N332A mutants. Three heterologous viruses were assessed
for each mutation and results are color coded with 3- to 5-fold reduction in neutralization activity shown in yellow, 5- to 10-fold reduction in orange, 10- to
100-fold reduction in red, and 100-fold reduction in dark red. V2/V3 speciﬁcity was assigned when plasma showed 3-fold reduction in at least 2 backbones.
The V2 MAbs CAP256.08 and PG9 and the V3 MAb PGT128 were used as positive controls and showed the expected activity.
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FIG 4 Mapping of CD4bs antibodies by binding and neutralization using the RSC3 protein. (A) Plasma
samples were tested for binding to the RSC3 protein (solid line) and the CD4bs mutant protein RSC3Δ371I/
P363N (dotted line) by ELISA. Shown are curves of 6 children with binding to the RSC3 protein but not the
mutant protein, similar to VRC01 and suggestive of CD4bs antibodies. PID14 showed equivalent binding to
both proteins and was used as a negative control. (B) The RSC3 protein was also used in a competition
neutralization assay to detect CD4bs antibodies in the same 6 participants. Neutralization of Du156.12, CAP45,
ConC, and Q23.17 was measured following incubation with RSC3. A reduction in neutralization of 30%
(dotted line) was considered positive. Five of the 6 children showed activity against one virus, most commonly
CAP45. VRC01 was used as a positive control, with RSC3 blocking neutralization of all 4 viruses as expected.
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mapping of these 4 samples was performed using additional chimeras, C4, C4GW, C6,
and C8, that contain point mutations in the MPER (21). PID3 and, to some extent, PID10
had a 4E10-like footprint characterized by potent neutralization of C4GW, C4, C8, and
C6 (Fig. 5A). Two samples, PID1_C and PID7, had similar patterns, neutralizing C4GW
and C8 but not C4 and C6, a footprint similar to that of Z13e.1 (Fig. 5A). None of the
four plasma samples showed neutralization of C3 and C7 (which contain the 2F5
epitope), suggesting that recognition of this N-terminal MPER region is uncommon.
These data indicate that the anti-MPER antibodies in children recognized an epitope
within the C terminus of the MPER, similar to bNAb 4E10.
To assess the contribution of the MPER-directed antibodies to broad neutralization
activity, adsorption and competition neutralization assays were performed using the
MPR.03 peptide. PID3, who had the highest titers against the HIV-2/HIV-1 MPER
chimeras, showed a signiﬁcant reduction in neutralization activity in both assays. This
effect was seen against C1C and COT6 (Fig. 5B) but not in another 3 heterologous
viruses (data not shown). In contrast, no reduction in neutralization activity was
observed for PID1_C, PID7, and PID10 against any of the viruses tested (data not
shown). Overall, MPER antibodies were therefore shown to contribute to breadth in
only 1/16 children in this cohort.
Antibodies directed to the gp120-gp41 interface detected in more than half of
the children. To determine whether children have antibodies directed at the gp120-
FIG 5 Mapping of anti-MPER neutralizing activity in four children. (A) Plasma samples from 4 children with high levels of neutralizing activity against the
HIV-2/HIV-1 MPER C1 and C1C constructs were tested against 6 additional chimeric constructs containing point mutations to map known MPER antibodies. Also
shown are the sequences carried by the MPER of each engrafted HIV-2/HIV-1 chimeric construct. Mutated amino acids are indicated in blue. Titers are shown
as ID50 and are color coded with HIV-2 used as a negative control. 2F5, 4E10, and Z13e1 were used as positive controls. (B) Plasma from PID3 was incubated
either with magnetic beads coated with MPR.03 peptide (left) or incubated directly with the MPR.03 peptide (right) to adsorb anti-MPER antibodies. MPER broad
neutralization activity against untreated (solid lines) and adsorbed (dotted lines) samples was tested against heterologous viruses C1C and COT6. Adsorption
of anti-MPER antibodies in PID3 reduced neutralization of heterologous viruses.
Ditse et al. Journal of Virology
September 2018 Volume 92 Issue 17 e00878-18 jvi.asm.org 8
 o
n
 February 28, 2020 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
gp41 interface, including the fusion peptide (FP), plasma samples were screened using
peptide competition assays, ELISAs, and neutralization assays with epitope-ablating
mutants. The FP9 peptide inhibited 30% neutralization against at least 2 of the 3
viruses (Du156.12, ConC, and BG505) in 7 children, suggesting the presence of fusion
peptide-directed antibodies (Fig. 6A). As described by Kong et al., we also observed
80% reduction in neutralization activity against all 3 viruses for VRC34, a fusion
peptide-speciﬁc antibody used as a positive control (22) (Fig. 6A). ELISA data demon-
strated binding responses to the FP9 peptide for 11 children (Fig. 6B), six of whom also
exhibited evidence of FP-mediated competition (Fig. 6B, red curves). The remaining ﬁve
ELISA-positive children did not show inhibition of neutralization (Fig. 6B, shown in
blue). Interestingly, no binding antibodies to FP9 were observed for PID1_C, although
FP9-speciﬁc neutralizing responses were detected by competition (Fig. 6A and B).
To further assess FP-directed responses in children, we also used a viral mutant
containing a threonine insertion after residue 514 in the FP of isolate BG505. This
mutation confers complete resistance to VRC34 (22). A 10- and 8-fold decrease in
neutralization activity against this mutant strain was observed for PID14 and PID15 (Fig.
6C), both of whom also had FP responses by ELISA and competition neutralization
assays (Fig. 6A and B), suggesting that the fusion peptide is a target for bNAbs in these
two children.
Since gp120-gp41 interface bNAbs 8ANC195, PGT151, 35O22, VRC34, and CAP248-2B
target distinct but overlapping epitopes (23), we tested mutants critical for each bNAb.
Three children had antibodies sensitive to deletion of the glycan at position 88 in
gp120, with fold effects from 10 to100, one of whom, PID12, was also shown to have
FP bNAbs. The N88 glycan is critical for epitope recognition for PGT151, 35O22, and
VRC34 (23) (Fig. 6C). We also observed sensitivity to the N88A and N234A mutations for
PID5 and for PID6 against the N234A mutation only, as has been reported for 8ANC195-
like antibodies (14) (Fig. 6C). Three plasma samples, including PID5, showed a minor
effect with N611D, and PID6 neutralization was reduced by N637A; both mutations
affect PGT151, 35022, and VRC34 neutralization.
We next screened plasma samples using the CAP45 CS-Mut virus that contains 6
mutations in the gp120-gp41 cleavage site, which we described previously (23). These
mutations mediate escape from PGT151 and CAP248-2B-like antibodies but result in
exposure of the MPER detected through increased neutralization sensitivity (23). As
previously reported, CAP45 CS-Mut was 100-fold more resistant to PGT151 but
showed enhancement of 35022 and 4E10 (Fig. 6C). A 4-fold reduction in neutralization
activity was observed against CAP45 CS-Mut in one child, PID13, suggesting that
PGT151/CAP248-like antibodies contribute to neutralization activity in this participant
(Fig. 6C). We saw enhanced neutralization activity in 3 participants (PID3, PID8, and
PID15), suggesting these children had MPER-directed or 35O22-like antibodies (Fig. 6C).
In support of this, we observed MPER activity in PID3 (Fig. 4A and B) and, to some
extent, PID8 (C1C titer of 188; data not shown). Overall, our data demonstrate that more
than half of children (9/16, 56%) develop antibodies targeting regions within the
gp120-gp41 interface.
Neutralization breadth in children is mediated by multiple antibody speciﬁc-
ities. Combining all the mapping data generated in this study, we noted that the
majority of children (10/16, 63%) developed more than one antibody speciﬁcity
(Fig. 7A). Most had 2 speciﬁcities, although 3 children had three speciﬁcities and one
child, PID5, developed antibodies targeting four different epitopes (Fig. 7B). None of the
children developed bNAbs that targeted the MPER epitope only. No association was
observed between neutralization breadth and the number of bNAb speciﬁcities de-
tected in each child’s plasma sample.
Mother-child pair develops antibodies targeting distinct bNAb epitopes. To
further understand factors associated with development of neutralization breadth, we
studied a mother-child pair over a 9-year period. The mother (PID1_M) was enrolled
into the study approximately 8 years after infection and had a viral load of 139,000 that
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FIG 6 Children develop antibody responses to the gp120-gp41 interface, including the fusion peptide. (A) A reduction in neutralization
of Du156.12, ConC, and BG505 was measured following incubation with the fusion peptide FP9. A cutoff of 30% (dotted line) was
considered signiﬁcant. Of the 16 children, 7 showed activity against 2 or 3 viruses that was FP directed. VRC34 was used as a positive
control. (B) Plasma samples from 16 children were assessed for binding to FP9 using ELISA. Samples where FP9 competed for
neutralization in panel A are shown in red, blue represents ELISA-positive samples where FP9 did not compete for neutralization, and
black represents samples that were negative for both binding and neutralization. VRC34 was used as a positive control. (C) Mapping
of responses using mutant viruses to the fusion peptide (THR514B), gp120-gp41 (residues 88, 234, 611, and 637), and the cleavage site
(CAP45 CS Mut that contains 6 mutations known to expose the MPER). The fold change in neutralization breadth for the mutants
relative to the wild-type strains is shown as a heat map for all 16 plasma samples. Loss of activity is shown in yellow (3- to 5-fold), orange
(5- to 10-fold), and red (10-fold), and enhancement is shown in blue. PGT151, 35O22, 4E10, VRC34, and CAP248-2B were used as
positive controls. The overall speciﬁcity is shown in the last column, with those in brackets derived from data shown in panels A and B.
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ﬂuctuated over time but remained high (Fig. 8A). Her CD4 count remained above 500
cells/ml. The child’s (PID1_C) viral load was greater than 2 million copies/ml at birth and
declined slowly over time but was above 100,000 copies/ml at 9 years. At enrollment
into this study the mother’s plasma neutralized 60% of viruses in the 22-virus panel
tested, rising to 100% over the next 9 years (Fig. 8B). In contrast, no neutralizing activity
was observed in the child at 3 months, but breadth emerged over time and by 6 years
of age onwards the child’s plasma also neutralized 100% of the viruses tested (Fig. 8B).
Geometric mean titers were 1,000 for both mother and child after more than 9 years
of infection.
We had initially mapped the 6- and 9-year postenrollment time point for the child
and mother, respectively. To examine the evolution of bNAb responses in the mother-
child pair we mapped the longitudinal samples (Fig. 8C). Comparison of CAP45 and
CAP45 K169E titers showed the development of a V2-glycan response from 3 years
onwards in the mother. This effect was veriﬁed in 2 different backbones (CAP45 and
BG505 [data not shown]). A slight V2 dependence was observed for the child at 6 and
7 years, suggesting that V2-glycan bNAbs were not a major speciﬁcity in the child. We
observed no V3 responses in either mother or child, as there were no differences
between the N332A mutant relative to the wild-type strain. CD4bs activity was seen in
the mother at later time points; however, this speciﬁcity was not evident in the child.
The child developed MPER binding antibodies from 2 years of age, which persisted until
6 years of age and then declined over time. No MPER activity was observed in the
mother. Overall, our data suggest that the mother-child pair developed different
antibody proﬁles, with antibodies directed at the V2-glycan and CD4bs epitopes
evolving in the mother while the major speciﬁcities mediating breadth in the child
could not be mapped.
DISCUSSION
Although many studies have examined the development and targets of bNAbs in
adults (14, 24–28), a limited number of studies have assessed these responses in
children following HIV-1 infection (4, 7, 15). We and others have shown that children
mount broader and more potent antibody responses than adults, which indicates
fundamental differences in the way children respond to HIV antigens (4, 7). In the
present study, we used several approaches to reveal the targets of bNAbs among a
large number of preselected HIV-1 subtype C-infected children. We observed that
although neutralizing antibody speciﬁcities were similar to those of adults, the majority
of children had bNAbs targeting multiple epitopes. This polyclonality may be due to the
long duration of infection and high viral loads in this group of children, features
strongly linked to the development of neutralization breadth in adults (10, 11, 24, 25,
29). These data support the notion that children mount stronger and more complex
responses to HIV antigens than adults, which may have implications for the immuno-
genicity of HIV vaccines in children.
FIG 7 The majority of children develop antibodies targeting multiple epitopes. (A) Pie chart showing a summary of mapped neutralization epitopes targeted
by plasma antibodies from children. (B) Breakdown of speciﬁcities detected in children with more than one bNAb. Shown in the last column is the total number
of mapped speciﬁcities.
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FIG 8 Mother-child pair develop antibodies that target distinct epitopes. (A) Longitudinal viral load
(circles) and CD4 counts (triangles) for mother-child pair. Mother’s data (PID1_M) are shown in red, and
(Continued on next page)
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Polyclonal bNAb responses in adults have been previously reported (10, 19, 30–32);
however, this occurs at a much lower frequency than that observed here in children,
where 63% had between 2 and 4 speciﬁcities. Our previous data from the CAPRISA
cohort suggested that of the 7 adult women who developed bNAbs, only 1 had more
than one speciﬁcity (33). Similarly, longitudinal studies from the protocol C adult cohort
demonstrated multiple bNAb speciﬁcities in only 3/42 (7%) participants (10). However,
this may be an underrepresentation, since many adult mapping studies are performed
earlier in infection than with the children in this study.
Examples of adults with multiple speciﬁcities following long-term infection have
been reported, such as the single donor from whom the antibodies 35O22 and 10E8
were isolated after 20 years of infection (34, 35). Furthermore, the transmitting mother
in this study was shown to have at least 2 bNAb responses. In this case, she was a highly
unusual viremic nonprogressor who maintained normal CD4 counts for over 17 years
and a median viral load of 85,000 copies/ml (Fig. 8). Collectively, these data suggest that
long duration of persistent exposure to high antigenic load, which is more common in
children, can facilitate high levels of bNAb activity targeting multiple neutralization
epitopes.
Previous reports have shown that bNAbs arise more rapidly in children and can be
detected within a year of infection (7). This was also seen in the longitudinal sampling
of PID1_C, where some neutralizing activity was detected by 1 year. Over the next 6
years this increased to 100% neutralization of the panel, remaining at these levels for
another 3 years. In adults, neutralization breadth generally takes up to 3 years to
emerge, although cases of earlier detection of neutralizing activity have been reported
(18, 25, 36). Further studies are needed to determine whether children have unique
immunologic features that shorten the normally long process associated with the
development of bNAbs. The isolation of MAb BF520.1 from an infant targeting the
V3-glycan epitope on the HIV envelope, which exhibited low levels of somatic hyper-
mutation and few indels, supports this possibility (15). Breadth in children may also be
the result of their ability to generate new B cell lineages for a longer period of time,
whereas data in adults suggests new bNAb speciﬁcities rarely emerge after 4 to 5 years
of infection (25, 29).
The majority of children had responses directed at the V2-glycan epitope. This is
similar to ﬁndings in adults (10, 19, 25, 32), suggesting that this antigenic site on the
HIV-1 envelope is dominant in adult and pediatric HIV infection. The high proportion of
CD4bs responses in this cohort may also be a consequence of the long duration of
infection, as this is a prerequisite for this class of antibodies, which requires the
accumulation of high levels of somatic hypermutation over many years (20, 37).
However, isolation and genetic characterization of CD4bs MAbs from children is needed
to address this question. Binding responses to the fusion peptide were observed in the
majority of children, similar to a subtype B adult cohort, where 42% of the participants
had this speciﬁcity (22). In contrast, MPER responses were rarely found in children,
which is similar to the case for adults (13, 31, 38, 39). Structural constraints in accessing
FIG 8 Legend (Continued)
the child’s data (PID1_C) are shown in blue. Stars indicate the time points used for plasma mapping.
Absolute CD4 counts with the median and 10th and 90th percentiles for normal uninfected children over
the ﬁrst 10 years of life are shown in gray (53, 54). (B, top) Kinetics of development of neutralization
breadth in the mother-child pair over a 9-year period. Shown is the percentage of viruses neutralized in
a 22-virus panel with mother shown in red and child in blue. (Bottom) Longitudinal geometric mean ID50
titers (GMT) of all viruses in the 22-virus panel for mother and child. (C) Mapping of the speciﬁcities over
time in mother and child. Longitudinal samples were assessed for V2-glycan using the K169E mutant in
CAP45 relative to the wild-type strain. V3-glycan-directed responses were assessed using the N332A
mutant in ConC relative to the wild-type strain. CD4bs activity was assessed by the RSC3 and the
RSC3Δ371I/P363N CD4bs mutant in ELISA. MPER responses were determined using the MPER
chimeric constructs C1 (black) and C1C (gray). Wild-type strains are shown in solid lines and closed
circles, and mutants are shown in dotted lines. Mother’s data (PID1_M) are shown on the left, and
the child’s data (PID1_C) are on the right. Mother’s samples were missing at time points 3, 6, and 7
years of the child’s age.
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the MPER on gp41 as well as the autoreactivity of MPER-targeting antibodies are
thought to be some of the factors that contribute to the restricted induction of
responses against this site (40, 41). PID3 had the highest titers of MPER bNAbs and
showed enhanced neutralization of the CS mutant, which has an exposed MPER region
(23). In addition, high titers of antibodies against the fusion peptide in PID3 further
supports the conclusion that gp41 was exposed on the virus that infected this child.
The presence of multiple antibody speciﬁcities did not correlate with neutralization
breadth, as exempliﬁed by PID5, who developed 4 distinct bNAb speciﬁcities but did
not neutralize all viruses in the panel. Despite the array of techniques used here,
neutralization breadth in some children could not be completely mapped, suggesting
the possibility that bNAbs with novel speciﬁcities were also present, as has been
reported in adult cohorts. In particular, breadth in PID1_C could not be clearly mapped,
and the lack of adsorption with gp120 suggested that the bNAbs were trimer speciﬁc
or targeted gp41. Isolation of MAbs from this child would therefore be of interest.
Mother-to-child transmission provides a unique setting to examine the role of viral
and host factors that shape bNAb responses. This study demonstrated that the mother-
child pair developed bNAbs targeting distinct neutralization epitopes. The high degree
of viral and host genetic relatedness suggests that multiple factors shape the devel-
opment of bNAbs. There was no neutralizing activity in the child at 3 months of age,
indicating that responses in the child arose de novo and that maternal bNAbs, if
present, had waned to below detectable levels. The bottleneck in HIV mother-to-child
transmission is well described, with children often becoming infected with a minor
variant (42, 43). Antibody speciﬁcities in both mother and child evolved continuously,
and studies are ongoing to examine viral evolution and escape pathways in this pair.
Most studies aimed at HIV vaccine development have been conducted in adults.
However, studies in infants have demonstrated that HIV vaccination induces strong
immune responses (44, 45). Importantly, Fouda et al. reported robust and durable
anti-V1V2 IgG antibody responses to MF59-adjuvanted HIV vaccines in HIV-exposed
infants compared with those of RV144 recipient adults (46). These differences in vaccine
responses between adults and infants were shown to be attributable to modulation of
gp120-directed responses by adjuvants (47). Our ﬁnding that children develop broader
and more potent responses to HIV infection suggests that they respond better to
vaccines than adults.
In summary, our study demonstrates that children who develop broad and potent
antibodies target multiple speciﬁcities directed at previously identiﬁed epitopes. This
suggests that children are fundamentally better at generating bNAb responses than
adults (1, 4, 6, 7, 46, 47). It will be important to understand how these responses are
induced during infection and whether this is due to the unique immunological envi-
ronment of the immature immune system that allows multiple B cell lineages to thrive.
Isolation and characterization of MAbs from children will also help to address this.
Importantly, our data suggest that children respond well to vaccine immunogens
currently under clinical evaluation. Testing of bNAb-based HIV vaccines in children
should therefore be a priority.
MATERIALS AND METHODS
Study population. This study included ART-naive, HIV-1 subtype C-infected PNPs and progressors
recruited from Kimberley and Durban, South Africa, as part of a study to determine the immunological
factors associated with nonpathogenesis in children (4). The PNP cohort consists of ART-naive children
with CD4 counts of 750 cells/mm3 and viral loads of 14,000 copies/ml who have not met the clinical
criteria for ART initiation. The progressor cohort consists of ART-naive children whose absolute CD4 count
had declined to 500 cells/mm3 and had viral loads of 70,000; these children are at the current
threshold of ART initiation (4) according to national guidelines for ART initiation at the time when the
participants were recruited. For this study, plasma samples collected in EDTA from 16 children with the
highest neutralization breadth were selected for epitope mapping. For child PID1_C (also known as
517-C), samples from the transmitting mother were also tested. Ethical approval was obtained from the
University of the Free State Ethics Committee, University of KwaZulu-Natal Biomedical Research Ethics
Committee, and University of Oxford Research Ethics Committee (4).
Adsorption of anti-gp120 antibodies. Anti-gp120 antibodies were depleted using monomeric
wild-type ConC gp120 covalently coupled to tosyl-activated magnetic beads as described previously (31,
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48, 49). Adsorbed plasma samples were assessed in ELISAs to conﬁrm depletion of anti-gp120 antibodies
and in the TZM-bl neutralization assay against HIV-1 to assess residual activity (31, 48, 49).
Neutralization assays. Neutralization was measured as the reduction in luciferase gene expression
following a single round of infection of TZM-bl cells with Env-pseudotyped viruses (50). Titers were
calculated as the 50% inhibitory concentration (IC50) or the reciprocal plasma dilution (ID50) causing a
50% reduction of relative light units (RLU) compared to results for the virus-treated or untreated control
wells (50). Mutations were made in the following backbones: TRO.11, ConC, Du156.12, CAP45.G3,
Du151.2, BG505 N332, and CAP256 SU. BG505 N332 is a BG505 strain where a glycan at position 332
was knocked in, and CAP256 SU is the superinfecting virus from CAPRISA participant CAP256. For
neutralization competition assays, peptides or proteins were added to each well at a concentration of
250 g/ml. This included the synthetic biotinylated fusion peptide, FP9-biotin, with the sequence
AVGIGAVFL (22), the MPR.03 peptide with the sequence KKKNEQELLELDKWASLWNWFDITNWLWYIRKKK
(51), and the resurfaced stabilized gp120 core (RSC3) and its CD4bs mutant, RSC3Δ3711/P363N (52).
Proteins/peptides were incubated with serially diluted MAbs or human plasma for 30 min at 37°C before
addition of pseudovirus. The mixture was further incubated for 30 min at 37°C. TZM-bl cells were added
at 0.5 million cells/ml and incubated for 48 h, followed by cell lysis and measurement of luciferase
activity.
Detection of antibodies targeting the MPER. Anti-MPER activity was measured using chimeric
HIV-2/HIV-1 MPER constructs (51). Plasma responses of an ID50 of 750 against either C1 or C1C were
considered positive, and these were further investigated using adsorption experiments. Adsorption
experiments were performed using streptavidin-coated magnetic beads (Dynal MyOne Streptavidin C1;
Invitrogen) incubated with biotinylated peptides carrying the MPR.03 sequence as described previously
(51). Adsorbed plasma samples were tested by ELISA to conﬁrm depletion of anti-MPER antibodies and
in TZM-bl neutralization assays to assess the contribution of MPER antibodies to breadth (51).
ELISA. MPER, RSC3, and fusion peptide ELISAs were performed as described previously (21, 22, 52).
Brieﬂy, 96-well ELISA plates (Corning, USA) were coated with 2 g/ml of protein/peptide overnight.
Coated plates were washed with phosphate-buffered saline (PBS) containing 0.05% Tween (dilution
buffer) and blocked with 5% goat serum, 5% skim milk in dilution buffer for 1 h at 37°C. A 100-fold
dilution of each plasma sample was added to the wells, titrated, and incubated for 1 h at 37°C. Unbound
antibodies were removed by 4 washes before addition of goat anti-human IgG peroxidase-conjugated
(KPL) at a 1:1,000 dilution. Following incubation with the secondary antibody, the wells were washed four
times and developed using 1-Step Ultra TMB substrate (Thermo Scientiﬁc, Waltham, MA, USA). The
reaction was stopped with 0.2 M H2SO4, and adsorbance was read at an optical density of 450 nm on a
microplate reader (Molecular Devices).
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